Oncology and Hematology - MedEd On The Go

1-16 of 74

NEW EPISODE
ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
MinuteCE®
ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
Aditya Bardia, MD, MPH, FASCO
0.50 program credits
- Aditya Bardia, MD, MPH, FASCO
0.50 program credits
NEW EPISODE
SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
MinuteCE®
SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
Erica L. Mayer, MD, MPH
0.50 program credits
- Erica L. Mayer, MD, MPH
0.50 program credits
NEW EPISODE
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
MinuteCE®
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
Aditya Bardia, MD, MPH, FASCO
0.50 program credits
- Aditya Bardia, MD, MPH, FASCO
0.50 program credits
MinuteCE®
Rapid Data Pulses From ASCO 2026: Emerging Data on Oral Targeted Strategies in Breast Cancer
Aditya Bardia, MD, MPH, FASCO; Erica L. Mayer, MD, MPH
0.50 credits 3 episodes
- Aditya Bardia, MD, MPH, FASCO
- Erica L. Mayer, MD, MPH
0.50 credits 3 episodes
Double-Class Refractory CLL in Community Practice: Current and Future Management
Double-Class Refractory CLL in Community Practice: Current and Future Management
CME/CE
Double-Class Refractory CLL in Community Practice: Current and Future Management
John C. Byrd, MD; William Mencia, MD, FACEHP
0.25 credits
- John C. Byrd, MD
- William Mencia, MD, FACEHP
0.25 credits
Navigating Treatment Sequencing After Frontline Treatment Failure in CLL
Navigating Treatment Sequencing After Frontline Treatment Failure in CLL
CME/CE
Navigating Treatment Sequencing After Frontline Treatment Failure in CLL
Jennifer R. Brown, MD, PhD; William Mencia, MD, FACEHP
0.25 credits
- Jennifer R. Brown, MD, PhD
- William Mencia, MD, FACEHP
0.25 credits
Personalizing First-Line Therapy for CLL
Personalizing First-Line Therapy for CLL
CME/CE
Personalizing First-Line Therapy for CLL
William Wierda, MD, PhD; Matthew S. Davids, MD, MMSc
0.25 credits
- William Wierda, MD, PhD
- Matthew S. Davids, MD, MMSc
0.25 credits
MinuteCE®
Partnering with Patients: Improving First-Line Treatment Selection in Upper GI Cancers Through Shared Decision-Making  
James M. Cleary, MD, PhD
0.50 credits 4 episodes
- James M. Cleary, MD, PhD
0.50 credits 4 episodes
Guideline Recommendations in First-Line Treatment of HER2-Negative Upper GI Cancers
Guideline Recommendations in First-Line Treatment of HER2-Negative Upper GI Cancers
MinuteCE®
Guideline Recommendations in First-Line Treatment of HER2-Negative Upper GI Cancers
James M. Cleary, MD, PhD
0.50 program credits
- James M. Cleary, MD, PhD
0.50 program credits
Pivotal Data in Anti-PD-1 Strategies for HER2-Negative Upper GI Cancers  
Pivotal Data in Anti-PD-1 Strategies for HER2-Negative Upper GI Cancers  
MinuteCE®
Pivotal Data in Anti-PD-1 Strategies for HER2-Negative Upper GI Cancers  
James M. Cleary, MD, PhD
0.50 program credits
- James M. Cleary, MD, PhD
0.50 program credits
Distinguishing First-Line Treatment Adverse Event Profiles in HER2-Negative Upper GI Cancers
Distinguishing First-Line Treatment Adverse Event Profiles in HER2-Negative Upper GI Cancers
MinuteCE®
Distinguishing First-Line Treatment Adverse Event Profiles in HER2-Negative Upper GI Cancers
James M. Cleary, MD, PhD
0.50 program credits
- James M. Cleary, MD, PhD
0.50 program credits
Quick Case: Strategizing Treatment Selection in HER2-/PD-L1+ Gastric Cancer
Quick Case: Strategizing Treatment Selection in HER2-/PD-L1+ Gastric Cancer
MinuteCE®
Quick Case: Strategizing Treatment Selection in HER2-/PD-L1+ Gastric Cancer
James M. Cleary, MD, PhD
0.50 program credits
- James M. Cleary, MD, PhD
0.50 program credits
Resectable Head & Neck Cancer: A Team-Based Approach to Perioperative Immunotherapy
Resectable Head & Neck Cancer: A Team-Based Approach to Perioperative Immunotherapy
CME/CE
Resectable Head & Neck Cancer: A Team-Based Approach to Perioperative Immunotherapy
Robert Haddad, MD; Ravindra Uppaluri, MD, PhD
0.25 credits
- Robert Haddad, MD
- Ravindra Uppaluri, MD, PhD
- Nancy Lee, MD, FASTRO
0.25 credits
The Evolving Landscape of Resectable Locally Advanced HNSCC
The Evolving Landscape of Resectable Locally Advanced HNSCC
MinuteCE®
The Evolving Landscape of Resectable Locally Advanced HNSCC
Ravindra Uppaluri, MD, PhD
0.75 program credits
- Ravindra Uppaluri, MD, PhD
0.75 program credits
Multidisciplinary Collaboration Facilitates Multimodality Therapy
Multidisciplinary Collaboration Facilitates Multimodality Therapy
MinuteCE®
Multidisciplinary Collaboration Facilitates Multimodality Therapy
Douglas Adkins, MD; Ravindra Uppaluri, MD, PhD
0.75 program credits
- Douglas Adkins, MD
- Ravindra Uppaluri, MD, PhD
- Nancy Lee, MD, FASTRO
0.75 program credits
Applying Perioperative ICIs in Clinical Practice
Applying Perioperative ICIs in Clinical Practice
MinuteCE®
Applying Perioperative ICIs in Clinical Practice
Douglas Adkins, MD
0.75 program credits
- Douglas Adkins, MD
0.75 program credits

Prev
1
2
3
4
5
Next

1/5